Viatris Inc. (VTRS) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

VTRS was mentioned in a general market update today, which noted mixed stock index performance. The broader market is being influenced by ongoing earnings releases, geopolitical tensions, and falling crude oil prices. A lower yield on the 10-year note also contributed to the market sentiment. The VIX volatility index remains subdued, indicating a stable trading environment with a lack of significant market fear. Investors should monitor upcoming earnings reports and geopolitical developments for potential market shifts.

VTRS|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NMS

Country

United States

Website

viatris.com

Symbol

VTRS

Description

Viatris Inc. is a global healthcare company focused on providing a diverse portfolio of medicines across various therapeutic areas. The company's core business revolves around the development, manufacturing, and distribution of prescription brand drugs, generic drugs, complex generics, and biosimilars. Viatris serves a broad range of markets, including North America, Europe, China, and emerging markets, offering products in areas such as cardiovascular health, oncology, and respiratory care. Its value proposition lies in its extensive product offerings, encompassing oral solid doses, injectables, and complex formulations, which are distributed through multiple channels to reach patients worldwide. Strategic collaborations with other pharmaceutical companies further enhance its product pipeline and market reach, solidifying its position in the competitive healthcare landscape.

VTRS|Earnings Snapshot

Earnings Summary

Viatris Inc. is a global healthcare company operating in the Drug Manufacturers - Specialty & Generic industry, providing a diverse portfolio of medicines across various therapeutic areas including cardiovascular health, oncology, and respiratory care. The company focuses on the development, manufacturing, and distribution of prescription brand drugs, generics, complex generics, and biosimilars, serving markets worldwide. In its most recent reported quarters, Viatris demonstrated an upward trend in earnings per share (EPS) and revenue. For Q2 2026, the company reported an actual EPS of 0.62, exceeding the estimate of 0.55578, and revenue of $3.58 billion, surpassing the prior quarter's revenue of $3.25 billion (Q1 2025). This follows a pattern of exceeding EPS estimates in Q3 2025 (0.67 actual vs. 0.6174 estimate) and Q2 2025 (0.62 actual vs. 0.55578 estimate), though Q1 2026 saw a slight miss with actual EPS of 0.59 against an estimate of 0.6106, alongside revenue of $3.517 billion against an estimate of $3.424 billion. Historically, Viatris has shown a mixed but generally positive growth trajectory, beating analyst EPS estimates in three of the last four reported quarters (Q2 2025, Q3 2025, Q4 2025) and exceeding revenue estimates in the most recent reported quarter (Q4 2025). Recent news highlights positive analyst sentiment, with Barclays raising its price target and maintaining an Overweight rating, citing strong first-quarter performance and robust commercial execution, particularly in Greater China. The acceptance of the New Drug Application for its fast-acting meloxicam by the FDA is a significant development, potentially expanding its therapeutic offerings in pain management. Additionally, the company reaffirmed its full-year 2026 revenue guidance and its quarterly dividend, indicating operational stability despite an interim CFO appointment. Investors will be watching for further updates on the FDA review process for the acute pain drug and continued execution on the company's growth strategy in key regions and product development for future quarters.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$0.61	-	-
Q1'26	$0.61	$0.59	-3.4%
Q4'25	$0.55	$0.57	+3.4%
Q3'25	$0.62	$0.67	+8.5%
Q2'25	$0.56	$0.62	+11.6%
Q1'25	$0.49	$0.50	+1.6%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$3.7B	-	-
Q1'26	$3.4B	$3.5B	+2.7%
Q4'25	$3.3B	$3.7B	+10.7%
Q3'25	-	$3.8B	-
Q2'25	-	$3.6B	-
Q1'25	-	$3.3B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

VTRS Stock Snapshot

VTRS is currently trading at $16.30, giving Viatris Inc. a market cap of 18.46B. Today's range spans $16.21–$16.43, with shares opening at $16.43 and moving up $0.04 (0.2%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 59/100.

Over the past year VTRS has traded between $8.19 and $17.53 - the current price is +99.0% off the 52-week low and -7.0% from the high. 19 analysts cover the stock with a Buy consensus and a mean 12-month target of $18.06 (range $12.00–$23.00), implying upside of +10.8%.

Algorithmic and quant fund activity in VTRS tends to intensify when the technical score crosses the 86/100 threshold - systematic models in large-cap Healthcare names trigger entry signals at these levels, adding momentum to what may have started as fundamental-driven buying. Signal: BUY. Sentiment: neutral (59/100). Price: $16.30 (in the upper portion of its 52-week range). Annual range: $8.19–$17.53.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (59/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $16.30 (in the upper portion of its 52-week range), VTRS's position within the $8.19–$17.53 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

News Sentiment Analysis

Sentiment gathered from recent headlines

59/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Argus has increased its price target for Viatris (VTRS) from $15 to $18, signaling a more optimistic view on the company's prospects. This adjustment reflects analyst confidence in Viatris's strategic direction and potential for future performance. Traders should monitor the company's execution against its strategic plans.

What did this article say?

This market update places VTRS within a broader context of mixed stock index performance on a Wednesday. The report notes ongoing earnings releases and geopolitical tensions influencing market sentiment, alongside falling crude oil prices and a lower yield on the 10-year note. The VIX volatility index remains subdued, indicating a lack of significant market fear.

What did this article say?

Opus Genetics highlighted its inherited retinal disease gene therapy pipeline, with two programs in the clinic and three more anticipated within 12 months. The company is leveraging established capsids and promoters to mitigate development risk. A key near-term catalyst is September data from the BEST1 Phase 1/2 trial, which will inform dose escalation or pivotal study decisions. Opus also noted its presbyopia program partnered with Viatris (VTRS) has an October PDUFA date that could generate royalty and milestone revenue.

What did this article say?

Viatris (VTRS) is gaining investor attention following the FDA's acceptance of its New Drug Application for MR-107A-02, a fast-acting, non-opioid meloxicam formulation targeting acute pain. This development comes amidst recent share price gains and a significant discount suggested by intrinsic value estimates, prompting a re-evaluation of the company's valuation. Investors are weighing pipeline progress against historical earnings pressures.

What did this article say?

Despite a recent 58.2% stock price surge over six months, analysts express caution regarding Viatris (VTRS). The company's long-term revenue growth of 1.1% annually over five years is considered tepid, and earnings per share (EPS) have declined by 9.2% annually during the same period. These factors suggest potential underperformance despite short-term momentum.

What did this article say?

The acute myocardial infarction (AMI) market is projected for significant growth, with an expected CAGR of 13% from 2026 to 2036, fueled by increasing cardiovascular disease prevalence and an aging global population. Innovations in diagnostic tools and the introduction of rapid treatments are key drivers. Viatris (VTRS) is noted for its involvement with Selatogrel, an emerging therapy contributing to this expanding market landscape.

What did this article say?

The U.S. Food and Drug Administration (FDA) has accepted Viatris' (VTRS) New Drug Application (NDA) for its fast-acting, non-opioid pain therapy. This acceptance marks a significant step forward in the development of a new pain management option. The therapy aims to provide relief without the risks associated with opioid use. Investors will be watching for further regulatory updates and potential market entry.

What did this article say?

Barclays has raised its price target for Viatris (VTRS) to $22 from $17, while maintaining an Overweight rating. This adjustment suggests continued positive sentiment from the analyst firm regarding the company's prospects. The previous consensus price target was $18.25.

What did this article say?

Callodine Capital Management has fully divested its stake in Algonquin Power & Utilities, selling shares valued at approximately $37.28 million. Following this liquidation, VTRS (Viatris Inc.) has emerged as a top holding for the fund, representing 7.7% of its assets under management. This strategic shift by a significant investor highlights Viatris's current portfolio weight within Callodine's strategy.

What did this article say?

Viatris exceeded Wall Street expectations for both revenue and non-GAAP earnings per share in the first quarter. This outperformance was fueled by robust commercial execution, particularly in Greater China, where demand for cardiovascular products surged. The company also benefited from contributions from new product launches in North America and ongoing operational efficiencies.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

VTRS·Viatris Inc.

EPS

Revenue

VTRS Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More